A Trial of Intranasal Corticosteroids to Treat Childhood OSA Syndrome

• Published in: Chest Vol. 162; no. 4; pp. 899 - 919
• Main Authors: Tapia, Ignacio E., Shults, Justine, Cielo, Christopher M., Kelly, Andrea B., Elden, Lisa M., Spergel, Jonathan M., Bradford, Ruth M., Cornaglia, Mary Anne, Sterni, Laura M., Radcliffe, Jerilynn
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2022; American College of Chest Physicians
• Subjects: Abdominal Muscles - abnormalities; Adrenal Cortex Hormones - therapeutic use; Blepharoptosis; Child; Cryptorchidism; double-blind method; fluticasone; Hip Dislocation, Congenital; Humans; intention-to-treat analysis; Male; Polysomnography; Quality of Life; randomized controlled trial; Sleep Apnea, Obstructive; Sleep: Original Research; Strabismus; Tonsillectomy - methods; double-blind method; fluticasone; intention-to-treat analysis; PSG; OSA-18; randomized controlled trial; OSAS; INCS; NOSE; OAHI; CHOP; REM; AOM
• ISSN: 0012-3692; 1931-3543
• DOI: 10.1016/j.chest.2022.06.026

Intranasal corticosteroids (INCS) are frequently used to treat OSA syndrome (OSAS) in children. However, their efficacy has not been rigorously tested. Do INCS result in improved OSAS symptoms, polysomnography findings, behavior, and quality of life compared with placebo? In this randomized, double-blind, placebo-controlled trial, children with OSAS aged 5 to 12 years (N = 134) were randomized 2:1 to receive 3 months of INCS or placebo. Children in the INCS arm were then re-randomized to receive 9 months of INCS or placebo. Polysomnography, symptoms, and neurobehavioral findings were measured at baseline, 3 months, and 12 months. The primary outcome was change in obstructive apnea hypopnea index (OAHI) at 3 months, available for 122 children. The secondary outcome was OAHI change at 12 months, available for 70 children. Median (interquartile range) age and OAHI at baseline for the entire group were 7.9 (6.3 to 9.9) years and 5.8 (3.6 to 9.7) events per hour. OAHI changes at 3 months (–1.72 [–3.91 to 1.92] events per hour) and 12 months (–1.2 [–4.22 to 1.71] events per hour) were not different between the two groups (P = not significant). OSAS symptoms and neurobehavioral results did not differ between the INCS and placebo groups at 3 and 12 months. The 38 children who received INCS for 12 months reported a significant OAHI decrease from 7.2 (3.62 to 9.88) events per hour to 3.7 (1.56 to 6.4) events per hour (P = .039). In children with OSAS, treatment with INCS did not result in significant polysomnography, neurobehavioral, or symptom changes at 3 and 12 months of treatment. Twelve months of INCS treatment resulted in a statistically significant but not clinically relevant OAHI reduction. ClinicalTrials.gov; No.: NCT02180672; URL: www.clinicaltrials.gov. [Display omitted]